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Abstract 
Apolipoprotein A-I (apoA-I) mimetic peptides have been pursued as new therapeutic agents 
for the treatment of atherosclerosis, yet their precise mechanism responsible for athero-
protection remains unclear. Like apoA-I itself, most of these peptides are capable of stimu-
lating cholesterol efflux from macrophages or foam cells, and some of them stimulate lecithin 
cholesterol acyltransferase (LCAT) activity in the reverse cholesterol transport (RCT) 
pathway. However, the ability of mimetic peptides to deliver cholesterol into hepatocytes 
(off-loading), the last step of the RCT pathway, has not been demonstrated. In this study, we 
compared a mimetic peptide D-4F to purified apoA-I, to address the role that mimetics play 
during the off-loading process. Both D-4F and apoA-I formed spherical nano-particles when 
reconstituted with cholesteryl ester and phospholipids. Compared to apoA-I, D-4F particles 
were 20 times more efficient in off-loading cholesterol to HepG2 hepatocytes with an ap-
parent Kt (transport) of 0.74 μg/mL. Furthermore, D-4F also facilitated cholesteryl ester 
offloading from HDL particles into HepG2 cells when it was pre-incubated with these HDL 
particles. Using an inducible HEK293 cell line, we demonstrated that these nano-particles 
were able to be taken up through SR-BI, a HDL selective receptor. Cholesterol uptake by 
HepG2 cells was completely blocked by a neutralizing monoclonal antibody against SR-BI, 
demonstrating that D-4F particles, similar to HDL, specifically off-loaded cholesterol through 
SR-BI. Overall our data provides evidence that D-4F is capable of mimicking apoA-I to form 
HDL-like particles, and off-loads cholesterol for catabolism and excretion, thus completing 
RCT.  
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1. Introduction 
Although the precise mechanism by which 
high-density lipoprotein (HDL) exerts its 
athero-protective effects remains to be determined, 
the inverse correlation of HDL cholesterol (HDL-C) 
levels and cardiovascular risk has been demonstrated 
in many clinical studies [1]. Recently, torcetrapib, a 
cholesteryl ester transfer protein (CETP) inhibitor, 
failed in the Phase III clinical study [2], in which pa-
tients receiving torcetrapib showed no significant 
atherosclerotic lesion change despite substantially 
higher levels of large size HDL [3]. Since then, the 
research focus has been dramatically shifted from 
HDL concentration to HDL compositions and func-
tions that include reverse cholesterol transport (RCT), 
anti-inflammation, anti-oxidation, anti-thrombosis 
and vessel relaxation [4-7]. HDL is still believed to 
play important roles in atherosclerosis protection. 
However, because of the lesson learned from torce-Int. J. Biol. Sci. 2009, 5 
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trapib, a detailed understanding of HDL function and 
its metabolism becomes essential for the development 
of new HDL therapies against atherosclerosis.   
Numerous studies have demonstrated that 
apoA-I protein plays an important role in atheropro-
tection. Overexpression of apoA-I decreased athero-
sclerosis in animal studies [8,9]. Infusion of com-
plexes of phospholipids and apoA-I or its genetic 
variant (R173C), apoA-IMilano, reduced the atheroscle-
rotic lesion size in animals and humans [10-13]. The 
beneficial effects of apoA-I have been demonstrated 
in all steps of RCT, the process by which excess cho-
lesterol is transported from peripheral tissues, in-
cluding atherogenic foam cells or macrophages in 
plaques, to the liver [14]: apoA-I interacts with phos-
pholipids to form pre-beta HDL; it initiates choles-
terol efflux through the ATP-binding cassette trans-
porter A1 (ABCA1) to remove excess cholesterol from 
peripheral cells; it activates lecithin cholesterol acyl-
transferase (LCAT) to convert cholesterol to choles-
teryl ester (CE) to form mature HDL; and it interacts 
with SR-BI to facilitate the delivery of cholesterol 
from mature HDL into hepatocytes [15-17].   
While there is a clear benefit in apoA-I infusion 
therapy, the monetary cost of apoA-I therapy would 
be immense. A search for cheaper alternatives to 
apoA-I protein yielded a number of apoA-I mimetic 
peptides [18]. These 18-22 amino acid amphipathic 
peptides mimic apoA-I's ability to reduce atheroscle-
rotic lesions [19]. They are structurally diverse, al-
lowing the selection of peptides with greater potency 
and better pharmacokinetic profiles than apoA-I it-
self. One of these peptides, D-4F, is an 18-amino acid 
peptide with a helical structure similar to the con-
sensus repeats of the apoA-I protein [20]. The pri-
mary structure of D-4F consists of D-amino acids 
only, thus is resistant to mammalian gastrointestinal 
enzymes with a good potential for oral administra-
tion. D-4F inhibited atherosclerosis in mouse and im-
proved anti-inflammatory function of HDL in mouse 
and several other species [21]. Like apoA-I itself, ex-
actly how D-4F exerts its atheroprotective effect re-
mains unclear. Both apoA-I and D-4F promoted 
ABCA1-dependent cholesterol efflux from macro-
phage, the first step of RCT process. But unlike 
apoA-I, D-4F did not activate LCAT in vitro [22]. 
There are no data available to show whether D-4F 
itself is able to deliver cholesterol to the liver or has 
any impact on this last step of RCT. In this paper, we 
demonstrate that D-4F peptide is able to form 
HDL-size particles. Similar to HDL, these particles 
are capable of delivering CE into HepG2 hepatocytes 
specifically through SR-BI. In addition, D-4F facili-
tates cholesteryl ester offloading from HDL particles 
into HepG2 cells when pre-incubated with HDL par-
ticles. 
2. Materials and Methods 
2.1. Reagents  
All chemical reagents and all cell culture re-
agents were obtained from Sigma and Invitrogen re-
spectively unless otherwise indicated. Native HDL 
and DiO-HDL (3, 3'-dioctadecyloxacarbocyanine) 
were purchased from Biomedical Technologies. 
2.2. Generation of HEK293 cells expressing SR-BI 
regulated by Tet-on inducible system 
A DNA fragment corresponding to the coding 
region of human SR-BI was subcloned into 
pTRE-tight plasmid (Clontech), at NotI sites, under 
the control of tetracycline regulated-promoter. Posi-
tive E. coli clones with the correct orientation were 
confirmed by restriction digestion and DNA se-
quencing. After amplification, pTRE-tight[SR-BI] 
plasmid was linearized and transfected into the 
HEK293 Tet-on Advanced Cell Line (Clontech) using 
Lipofectamine Transfection Kit (Invitrogen). This 
commercially available cell line stably expresses the 
optimized Tet-On Advanced reverse transactivator 
protein (rtTA-Advanced) that can strongly and rap-
idly activate transcription from a tetracy-
cline-responsive promoter (TRE) in the presence of 
Doxycycline (Dox, a tetracycline derivative). Stable 
transfected clones were selected in the presence of 
G418 (100 μg/mL) and hygromycin (20 μg/mL) to 
create a stable cell line containing the entire inducible 
system. Individual clones started to appear after 7-10 
days. These individual clones were then isolated and 
expanded in triplicate plates. One plate was frozen 
down, while the remaining two plates were grown in 
the absence and presence of 2 μg/mL of Doxycycline. 
The positive clones were confirmed by western blot 
analysis. The resulting cell line is named 
HEK293[TREtightSR-BI]. 
2.3. Western blot analysis 
After 48 hour incubation with different concen-
trations of Doxycycline, the HEK293[TREtightSR-BI] 
cells were lysed in RIPA buffer (Sigma). The protein 
concentration was determined using BCA kit (Pierce). 
After adding 2x sample buffer (Invitrogen), 20 μg of 
cell lysate was boiled, and the lysate was cleared by 
centrifugation. The supernatant was loaded onto 10% 
SDS–PAGE gels. Western blot analysis was per-
formed with polyclonal anti-SR-BI antibody (Novus 
Biologicals, NB400-113). Horseradish peroxi-
dase-conjugated secondary antibody and the en-
hanced chemiluminescent substrate system (Amer-Int. J. Biol. Sci. 2009, 5 
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sham) were used as a detection system. The signal 
was visualized by X-ray film (Roche Diagnostic). 
2.4. Generation of fluorescent (Bodipy-CE la-
beled) particles 
Reconstituted HDL and synthetic peptide parti-
cles were prepared according to Hirz and Scanu [23] 
with minor modifications. Briefly, 1 mg 
2-Oleoyl-1-palmitoyl-sn-glycero-3-phosphocholine 
(POPC), 0.5 mg triolein, 0.12 mg Bodipy®-CE, and 
0.09 mg dabcyl dicetyl amide quencher were com-
bined from solvent stocks in a 2 mL polypropylene 
screw cap tube. These components were then 
co-evaporated under a gentle argon stream, resus-
pended in 1 mL ethanol and dried again under argon 
to remove any traces of solvent, then thoroughly 
dried by a brief lyophilization. One mg of apoHDL 
(delipidated HDL), apoA-I (Biodesign) or D-4F in one 
mL buffer A (50 mM Tris pH 8.6, 150 mM NaCl, 1 
mM EDTA) was added to the dried components and 
resuspended by vortexing to form a cloudy suspen-
sion. The sample was then subjected to two rounds of 
probe sonication (5 X 1 min) using a Misonix Sonica-
tor 3000 with a microtip set at power level 6.5 in or-
der to induce particle formation. During this proce-
dure, the solution cleared noticeably. The co-sonicate 
was then fractionated by equilibrium density ultra-
centrifugation to isolate particles in the density range 
of 1.063 – 1.21 g/mL. In some of the experiments, 
samples were then passed through a G-50 column 
and dialyzed extensively against PBS buffer in the 
presence of 1 mM EDTA. Particle concentration was 
expressed in terms of protein concentration as deter-
mined by BCA assay (Pierce). Non-fluorescent parti-
cles were generated the same way as the fluorescent 
ones, except the Bodipy-CE is replaced with regular 
CE. The synthetic HDL particles were stable at 4°C for 
several months. 
2.5. Determination of particle size by native 
polyacrylamide gel eletrophoresis 
Twenty microliters of native HDL, reconstituted 
HDL and synthetic particles were mixed with 2X na-
tive loading dye (Invitrogen). Samples were loaded 
onto 4-20% gradient Tris-Glycine gel without boiling. 
The gel was run at 125V for 2.5 hours before stained 
by the SimplyBlue SafeStain from Invitrogen. The 
sizes of particles were compared with the High Mo-
lecular Weight marker from GE.   
2.6. Off-loading Assay 
HepG2 and HEK293[TREtightSR-BI] cell lines 
were maintained in a humidified 37 ºC incubator 
with 5% CO2. On day 0, 5,000 cells were plated with 
DMEM/FBS medium and switched to medium A 
(DMEM + 10% lipoprotein deficient se-
rum+Pen/Strep glutamine) after the cells were at-
tached to the plates. On day 2, cells were washed 
once with medium B (DMEM+0.5% essential fatty 
acid-free BSA+ Pen/Strep glutamine) and then 
pre-incubated in medium B with or without antibody 
C11 [24] for 30 min. After this pre-incubation, HDL 
labeled with 3, 3'-dioctadecyloxacarbocyanine 
(DiO-HDL) (Biomedical Technologies) or Bodipy-CE 
labeled particles were added to the wells. After an 
additional incubation at 37 °C for 2 hours, the cells 
were washed twice with medium B and twice with 
PBS containing 0.5% essential fatty acid free BSA fol-
lowed by fixation with Cytofix (Invitrogen) solution 
at 4ºC for 30 minutes. The cells are then washed and 
stained with 0.1% Hoechst 33342 nuclear dye (Invi-
trogen). Imaging studies were performed with an 
ArrayScan V3.5 (Thermo-Fisher). The nuclei and DiO 
fluorescence images were acquired sequentially using 
UV and 488 excitation wavelengths respectively, and 
an XF100 blue/green dual emission filter. Images 
were analyzed using the Cellomics Target Activation 
BioApplication, and a mean relative fluorescence per 
well was obtained. A minimum of 300 cells per well 
was evaluated for DiO and Bodipy. The neutralizing 
monoclonal antibody (C11) used in this study was 
kindly provided by Dr. Alessandra Vitelli. This anti-
body is generated by selection of a phage display li-
brary using CHO/SR-BI as selector and in turn con-
verted to whole human IgG4 [24]. 
 
3. Results 
3.1. Mimetic peptides form HDL-like particles 
Reconstituted HDL and synthetic particles were 
prepared as described in Materials and Methods 
containing protein component of either delipidated 
HDL (apoHDL), apoA-I or D-4F. The size of particles 
was determined using native polyacrylamide gel 
electrophoresis. As shown in Figure 1, the synthetic 
particles formed by apoA-I and D-4F are quite ho-
mogeneous and migrated similarly to spherical native 
HDL, between 8.2 nm and 12.2 nm markers. The 
similar density of bands suggested that the incorpo-
ration efficiency is similar between apoA-I and D-4F. 
When separated on FPLC using a Superose 6 column, 
the reconstituted HDL and synthetic particles eluted 
in the same fractions as native HDL, and under the 
electronic microscope (EM) they had a spherical ap-
pearance similar to native HDL (Cianetti et al, un-
published data). Int. J. Biol. Sci. 2009, 5 
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Figure 1. Native polyacrylamide gel picture of native HDL 
and reconstituted particles. To prepare synthetic particles, 
POPC, TG and CE were mixed proportionally and dried to 
completion under argon gas. A protein component, 
apoHDL, apoA-I or D-4F in buffer was then added to the 
pellet. The sample
 was sonicated with a microtip
 sonicator 
to create the synthetic particles. 20µl of each sample was 
loaded onto a native acrylamide gel. After running at 90V 
for 2 hours, the gels were stained with Coomassie blue. 
Lane 1, marker; Lane 2, synthetic D-4F particles; Lane 3, 
synthetic apoA-I particles; Lane 4, reconstituted apoHDL 
(rHDL) particles; Lane 5, native HDL (nHDL). 
 
3.2. Particles formed by mimetic peptide is ca-
pable of off-loading CE into liver cells 
HDL labeled with 3, 
3'-dioctadecyloxacarbocyanine (DiO-HDL) was used 
to test HDL-CE off-loading. When compared with 
native HDL, DiO-HDL has 
similar electrophoretic mobility 
and apolipoprotein content, as 
well as similar binding proper-
ties [25]. Figure 2A shows that DiO-HDL can be taken 
up by HepG2 cells in a dose–dependent manner. To 
monitor the cholesteryl ester uptake by HepG2 from 
reconstituted HDL (rHDL) and synthetic particles, 
bodipy labeled cholesteryl ester (Bodipy-CE ) was 
used to make these rHDL or synthetic particles. Fig-
ure 2B shows that the reconstituted HDL particles 
were able to load Bodipy-CE into HepG2 cells. The 
amount of Bodipy-CE that gets into the cells is ex-
pressed as relative fluorescence in cells and correlates 
well with the titration of particle concentrations. Fig-
ure 2C indicates that the synthetic particles formed by 
apoA-I or D-4F can off-load their CE into HepG2 
cells. The off-loading efficiency was analyzed as a 
function of concentration by nonlinear regression us-
ing the Prism™ software. Vmax for Bodipy-CE 
off-loading, is 176, 107 and 162 µg/mL/h for rHDL, 
apoA-I and D-4F, respectively. The apparent trans-
port constant Kt for rHDL, apoA-I and D-4F particles 
is 11.5, 10.4 and 0.74 μg/mL, respectively. Vmax / Kt is 
15.3 h-1 for rHDL, 10.28 h-1 for apoA-I and 219 h-1 for 
D-4F, demonstrating the off-loading for D-4F parti-
cles is 20 times more efficient than apoA-I particles 
and 14.3 times more efficient than rHDL particles. 
The Kt of rHDL is quite consistent with the reported 
16 μg/mL dissociation constant for native HDL [26]. 
Based on these data, we propose that D-4F can not 
only bind to HepG2 cells, but can also to form a much 
more "productive complex" for delivery of CE into 
HepG2 cells.   
 
Figure 2. Cholesterol uptake by 
HepG2 cells. HepG2 cells were 
incubated with indicated amounts of 
DiO-HDL or Bodipy-CE labeled 
particles, with or without preincu-
bation of D-4F. The selective uptake 
was determined as described in 
Experimental Procedures. Data are 
presented as mean relative fluo-
rescence units from triplicate or 
duplicate determinations. Error 
bars represent ±SD. Panel A), cho-
lesterol uptake of DiO-HDL. Panel 
B), cholesterol uptake of Bodipy-CE 
labeled rHDL. Panel C), cholesterol 
uptake from Bodipy-CE labeled rHDL (○), apoA-I (∆) and D-4F synthetic particles (●). The uptake efficiency for each particle 
was analyzed as a function of concentration by nonlinear regression using Prism™ software. Panel D), Percentage increase 
of cholesterol uptake of DiO-HDL (4 µg/mL) with preincubation of D-4F. (*P<0.05 versus no D-4F control). Int. J. Biol. Sci. 2009, 5 
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3.3. D-4F facilitates HDL delivery 
It has been suggested that D-4F could work in-
dependently to exert some of its effects such as in-
creasing endothelium- and eNOS-dependent vasore-
laxation, but it needs apoA-I to execute its full func-
tion and reduce the vessel wall thickness in vivo 
[27-29]. Consistent with this hypothesis, when ad-
ministered into mouse, a majority of D-4F is found to 
be associated with HDL fractions in mouse plasma 
[30]. Since integrated D-4F could potentially change 
the lipoprotein and lipid composition of HDL, and in 
turn affect its function, D-4F could act either as an 
extra apoA-I protein to facilitate the uptake of 
HDL-CE, or as a competitor to prevent the uptake of 
HDL-CE when administered into animals. To address 
these two possibilities, we performed the following 
experiments. The DiO-HDL and rHDL particles were 
preincubated with different concentrations of D-4F at 
37ºC for 1 hour before being added to HepG2 cells. 
Figure 2D shows preincubation of D-4F leads to in-
creased DiO-HDL uptake in a dose-dependent man-
ner. D-4F did not compete with apoA-I in the particle 
to block the CE off-loading. The average relative DiO 
fluorescence in HepG2 cells with D-4F at 200 and 
100ug/mL is significantly higher than those with no 
D-4F (P<0.05).   
 
 
 
3.4. Off-loading CE is mediated through SR-BI 
To demonstrate that the synthetic particles de-
liver their CE core into cells through SR-BI, we used a 
Doxycycline-regulated inducible SR-BI recombinant 
cell line. Doxycycline-regulated systems which allow 
a high degree of control over the expression levels of 
a protein of interest, provide a tool for studying pro-
tein regulation and function in eukaryotic cells [31]. A 
Doxycycline-inducible HEK293 cell line expressing 
SR-BI was generated using Clonetech's Tet-on induc-
ible expression system. The expression of SR-BI was 
induced by adding Doxycycline into culture medium 
for 48 h. Western blots shown in Figure 3A demon-
strate that SR-BI expression is induced in a 
dose-dependent manner. CE-selective uptake was 
observed when DiO-HDL particles (or Bodipy-CE 
labeled particles, Figure 5) were incubated with 
HEK293 cells expressing SR-BI. Figure 3B shows that 
the amount of fluorescence getting into the cell was 
dependent on the amount of SR-BI expressed on the 
surface of the HEK293 cells. This observation indi-
cates that SR-BI is at least one of the transporters that 
mediated CE uptake.   
 
 
Figure 3. A) Induced SR-BI expression in HEK293 cells. 
Expression of SR-BI was induced by different concentra-
tions of Doxycycline as indicated on the figure. Western 
blot analysis was performed with anti-SR-BI antibody 
(Novus Biologicals, NB400-113). Horseradish peroxi-
dase-conjugated secondary antibody and the enhanced 
chemiluminescent substrate system (Amersham) were 
used. B) Bodipy-CE uptake is dependent on the expression 
level of SR-BI. After Doxycycline induction, 
HEK293[pTRE-tight-SR-BI] cells were incubated with 10 
µg/mL DiO-HDL. The selective uptake was determined as 
described in Experimental Procedures. Data are presented 
as mean relative fluorescence units from triplicate or du-
plicate wells. Error bars represent ±SD. 
 
3.5. Off-loading CE from rHDL or peptide syn-
thetic particles is solely through SR-BI 
To determine whether this uptake is solely 
through SR-BI, we used an SR-BI specific neutralizing 
antibody, C11. C11 was generated from a phage dis-
play library and has very high affinity for SR-BI re-
ceptor [24]. C11 effectively blocks SR-BI-mediated 
cholesterol uptake and cholesterol efflux [24]. Figure 
4A and 4B show the actual fluorescent images under 
microscope. Green color represents Bodipy fluores-
cence and blue represents Hoechst nuclear dye stain-
ing. The Bodipy fluorescence uptake was greatly re-Int. J. Biol. Sci. 2009, 5 
 
http://www.biolsci.org 
642
duced when antibody C11 was incubated with 
HepG2 cells at 10 µg/mL. As shown in Figure 4C, 
C11 antibody at 1 µg/mL and 10 µg/mL significantly 
reduced Bodipy-CE uptake from rHDL as demon-
strated by array scan. At 10 µg/mL, C11 antibody 
was able to block Bodipy-CE uptake completely. CE 
uptake from apoA-I and D-4F synthetic particles was 
also blocked by C11 antibody as shown in Figure 4D, 
indicating that CE off-loading to the liver cells from 
these particles are solely mediated by SR-BI. These 
data were confirmed with C167, another neutralizing 
monoclonal antibody against SR-BI [24]. 
CE uptakes of rHDL and D-4F synthetic parti-
cles through SR-BI are confirmed with a SR-BI induc-
ible-expressing cell line. In Figure 5, 5 µg/ml 
Bodipy-labeled HDL and D-4F synthetic particles 
were incubated with HEK293[pTRE-tight-SR-BI] after 
Doxycycline induction. Similar to HepG2 cells, the 
selective uptake of Bodipy fluorescence was blocked 
by SR-BI specific antibody. 
 
 
 
 
 
 
Figure 4. Cholesterol uptake by HepG2 cells is blocked by SR-BI specific blocking antibody C11. HepG2 cells were in-
cubated with indicated amount of Bodipy-CE labeled particles, with or without antibody C11. The selective uptake was 
determined as described in Experimental Procedures. Panel A), picture taken under fluorescent microscope. HepG2 cells 
were incubated with 25 µg/mL of Bodipy-CE labeled rHDL in the absence of antibody. The green signal represents Bodipy; 
the Hoechst nuclear staining is in blue. Panel B), picture taken under fluorescent microscopic. HepG2 cells were incubated 
with 25 µg/mL of Bodipy-CE labeled rHDL in the presence of 10 µg/mL antibody C11. The green signal represents Bodipy; 
the Hoechst nuclear staining is in blue. Panel C), cholesterol uptake of Bodipy-CE of rHDL particles at different concen-
trations in the absence of C11 (○), in the presence of 1µg/mL C11(∆) and in the presence of 10µg/mL C11(▲ ). Panel D), 
cholesterol uptake of Bodipy-CE synthetic particles at 25µg/mL in the presence (empty bar) or absence of 10µg/mL C11 
antibody (solid bar). Error bars represent standard deviations of relative fluorescence from triplicate determinations.  Int. J. Biol. Sci. 2009, 5 
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Figure 5. Bodipy-CE uptakes of reconstituted HDL and D-4F synthetic particles are mediated through SR-BI. After 
Doxycycline induction, HEK293[pTRE-tight-SR-BI] were incubated with 5 µg/ml Bodipy-labeled HDL and D-4F synthetic 
particles. The selective uptake was determined as described in "Methods". Anti-SR-BI antibody (C11, 10 µg/ml) was used in 
this study. Data were presented as mean relative fluorescence units from triplicate or duplicate wells. Error bars represent 
±SD. The uptake of Bodipy fluorescence was blocked by SR-BI specific antibody. 
4. Discussion 
HDL mimetic peptides with 18-22 amino acids 
are designed to mimic apoA-I's ability to form class A 
amphipathic helices without sharing sequence simi-
larity to apoA-I protein. On one hand, their sequence 
diversity offers a potential opportunity to surpass 
apoA-I's atheroprotective effects. On the other hand, 
mimicking all of the atheroprotective properties of 
apoA-I protein (243 amino acids) that contains 10 
amphipathic helices with one peptide containing a 
single helix could be a challenge. Both mutagenesis 
studys and human genetic data suggest that different 
regions of apoA-I are important for different func-
tions. For example, the mutations at the N-terminal 
(2-7 helices) are associated with familial amyloidosis 
while the mutations at the C-terminal (4-10 helices) 
are associated with LCAT activation, despite the fact 
that these mutations are all associated with low HDL 
level in plasma. The binding specificity of apoA-I 
with SR-BI is not affected substantially by the dele-
tion of the first helix (1-59 amino acid) or of the heli-
ces 8-10 (185-243 amino acid) of apoA-I, however the 
double mutations of apoA-I at helix 4 
(D102A/D103A), or at helix 6 (R160V/H162A) alter 
its interaction properties with SR-BI [32,33]. In this 
paper, we have assessed whether D-4F, a single am-
phipathic helix, can represent wild type apoA-I pro-
tein to form HDL-like particles and to off-load cho-
lesteryl ester into the liver cells. We prepared the 
synthetic (apoA-I or peptide) particles containing 
phospholipids, CE, TG and apoA-I or D-4F. These 
particles exhibited similar size and shape to native 
HDL. The off-loading experiments were performed 
with HepG2 (human) and 1C1C (mouse) hepatoma 
cell lines (data not shown). Compared to rHDL and 
the apoA-I particles, D-4F particles are more efficient 
in delivering its CE core with more than a 14- and 
20-fold higher Vmax / Kt, respectively, indicating that 
D-4F is superior in its ability to deliver CE into 
HepG2 cells. 
Although we demonstrated that D-4F is capable 
of delivering CE to liver cells, we did not know which 
receptors are associated with this uptake process. We 
hypothesized that SR-BI is the major receptor respon-
sible for the uptake since it selectively uptakes HDL 
cholesterol. To assess the possibility that SR-BI can 
mediate CE uptake for D-4F particles, we prepared a 
human embryonic kidney (HEK293) cell line stably 
expressing SR-BI under control of a tetracycline re-
sponsive element. Similar to apoA-I and native HDL 
particles, D-4F particles were able to deliver CE to the 
cells after Doxycycline induction and this was com-
pletely blocked by anti-SR-BI antibody (Fig. 5), indi-
cating that D-4F is capable of delivering cholesteryl 
ester though the HDL receptor, SR-BI. 
The use of peptide mimetics to improve protein 
function is a powerful tool, and may lead to novel 
therapeutic agents for the treatment of various dis-
eases. For example, the GLP-1 mimetic peptide, 
Albiglutide, has better PK/PD profile than GLP-1 
itself and is already in phase II clinical trials. Mimet-
ics could be particularly useful when the target pro-
tein is too big or has a short half-life. Amphipathic 
properties are shared by many different apolipopro-
teins such as apoA-I, apoE and apoB. An ideal apoA-I 
mimetic would be able to mimic one, many or all 
functions of the apoA-I protein selectively, without 
mimicking the functions of any other apolipoproteins 
(such as apoB or apoE). ApoB and apoE both deliver 
cholesterol to the liver through the LDL receptor. To 
demonstrate that the LDL receptor is not the mecha-Int. J. Biol. Sci. 2009, 5 
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nism by which D-4F delivers CE to liver cells, we 
performed an off-loading experiment using 
LDLR-expressing HEK293 cells. D-4F particles were 
not able to deliver CE to the cells by LDL receptors, 
while apoB containing LDL particles were capable of 
delivering CE to cells in a LDLR dependent fashion 
(data not shown). Many other receptors or transport-
ers on the cell surface besides LDL receptors and 
SR-BI might also be involved in the peptide delivery. 
To further rule out such a possibility, we chose an 
monoclonal antibody which selectively recognizes 
SR-BI and blocks SR-BI mediated cholesterol delivery 
[24]. With this antibody, we demonstrated that the 
off-loading of cholesteryl ester to HepG2 cells was 
inhibited completely, indicating that D-4F mimics the 
off-loading function of apoA-I, selectively transport-
ing cholesteryl ester into the liver cells solely through 
SR-BI.  
Data from genetic analysis suggests that the dy-
n a m i c  f l o w  r a t e  o f  c h o l e s t e r o l  f l u x  f r o m  p e r i p h e r a l  
foam cells to the liver, which is influenced by many 
factors, is considered to be more important than the 
static HDL mass alone [2]. For example, ApoA-IMilano 
carriers have low plasma HDL but are nevertheless 
protected from atherosclerosis, and SR-BI knockout 
mice have high plasma HDL but more advanced 
atherosclerotic lesions than their wildtype counter-
parts. The increase of HDL-C resulting from in-
creased cholesterol efflux from macrophages is con-
sidered beneficial, while the increase of HDL-C from 
reduced off-loading by SR-BI is considered detri-
mental. D-4F, when dosed in animals, was reported 
to slow the progression of atherosclerotic lesion de-
velopment and increase cholesterol excretion without 
changes in plasma HDL level [34,35]. Our in vitro 
study demonstrated that compared with apoA-I, 
D-4F induced cholesterol efflux from macrophage 
[22] and delivered HDL-C to HepG2 cells in a much 
more efficient manner. Based on these observations, 
we propose that D-4F can increase the dynamic flow 
rate of RCT even though HDL-C level is not changed. 
Consistent with this hypothesis, human kinetics data 
have also suggested that the turnover rate of apoA-I 
is more variable than its production rate [36]. 
In vivo, the D-4F mechanism is much more com-
plicated. Studies showed that D-4F interacts with 
endogenous HDL and incorporates into the particles. 
We wanted to determine whether D-4F, when incor-
porated into HDL, could have an additive, synergistic 
or inhibitory effect on the delivery of cholesterol to 
liver cells. Our data showed that preincubation of 
D-4F with HDL enhanced the CE off-loading from 
HDL to HepG2 cells, which is consistent with the ob-
servation that additional D-4F could facilitate the 
HDL-C delivery back to the liver from peripheral 
tissues  in vivo [32]. These data provided additional 
biochemical evidence to support the working hy-
pothesis that administration of the apoA-I mimetic 
peptide, D-4F, enhances the reverse cholesterol 
transport process, and therefore induces lesion re-
gression in patients with acute coronary syndrome. 
There are several challenges in drug discovery 
and development when targeting HDL: 1) the 
mechanisms of HDL functions, HDL metabolism and 
HDL compositions/regulators are not completely 
understood; 2) good animal models have not been 
identified where both lipoprotein profile and athero-
sclerotic plaque composition represent the human 
condition; 3) very long and expensive large scale 
outcome trials are required because HDL levels are 
not yet accepted as a surrogate for therapeutic out-
come; 4) and no surrogate endpoint has been vali-
dated. The total amount of cholesterol uptake by liver 
may be a better indication since an increased liver 
cholesterol pool inhibits de novo cholesterol synthesis 
by down-regulating SREBP-1 and/or enhancing ex-
cretion by up-regulating genes involved in bile acid 
synthesis and secretion (e.g. CYP7α1, BSEP and 
ABCG5/8).  
In summary, we have demonstrated that D-4F is 
able to deliver cholesteryl ester to HepG2 cells 
through SR-BI 20 times more efficiently than apoA-I 
protein. In addition, D-4F facilitates cholesteryl ester 
off-loading from HDL particles to HepG2 cells when 
it is pre-incubated with HDL particles. This function 
of D-4F will help the SR-BI receptor to drive reverse 
cholesterol transport, transferring more cholesterol 
from peripheral tissues to the liver. We believe that 
this property of D-4F, along with its efflux capacity 
[34], contributes to its athero-protective effect and 
reduces atherosclerosis in mouse. Understanding this 
function and details of the mechanism of D-4F will 
facilitate rational design of other peptides and pro-
vide guidance for its proper application in clinical 
therapy.  
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